BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Featured in Seeking Alpha Article Discussing Its Disruption in Chronic Disease Market

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, was featured in a recent Seeking Alpha news article. The piece, titled “DarioHealth: Don’t Overlook This Mini Livongo,” discusses disruptors in the chronic disease market, such as Omada Health, Virta Health and Lark Health. The article specifically focuses on DRIO and the competition it brings to larger players like Livongo Health Inc. (NASDAQ: LVGO), which generated great returns for investors. The article reads, “After LVGO got bought out, I started to look for other digital health plays, specifically competitors to LVGO. Recently, I found a tiny company called DarioHealth (NASDAQ: DRIO) that had already increased 2-3x in the past few months. Despite this increase, however, I found that DRIO has substantial potential to appreciate even further, as I will discuss in this article.”

To view the full article, visit https://ibn.fm/x2x8S

About DarioHealth Corp.

DarioHealth is a leading, global digital-therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions driven by connected devices, data, high-quality software and coaching, the company makes the right thing to do the easy thing to do. The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. Its highly engaging, user-centric MyDario(TM) mobile app is used regularly by tens of thousands of consumers worldwide. DarioHealth is rapidly moving into new geographic markets to address chronic conditions using a performance-based approach to improve the health of users managing chronic disease. To learn more about the company and its digital health solutions, visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Volition Solves Liquid Biopsy’s “Needle in a Haystack” Problem; Achieves 180-fold (18,000%) Enrichment

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced the preprint release of…

2 days ago

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in NetworkNewsAudio APR on Urgent Need for Rare Disease Therapies

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases, is highlighted in…

4 days ago

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights,…

4 days ago

BioMedNewsBreaks — Caring Brands, Inc. (NASDAQ: CABR) Closes $4 Million Offering as Company Uplists to Nasdaq Capital Market

Caring Brands (NASDAQ: CABR) closed its underwritten U.S. public offering of 1,000,000 shares of common…

4 days ago

BioMedNewsBreaks — HealthLynked Corp. (OTCQB: HLYK) Appoints Duncan McGillivray as Chief Operating Officer

HealthLynked (OTCQB: HLYK) announced the appointment of Duncan McGillivray, MBA, as Chief Operating Officer. McGillivray…

5 days ago

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies 

Soligenix (NASDAQ: SNGX), announces its inclusion in a BioMedWire editorial examining the urgent rise of…

1 week ago